膝关节手术中氨甲环酸的研究——一项多中心随机对照试验
这项双盲、安慰剂对照、多中心随机对照试验纳入5家新西兰中心2014年7月至2015年11月连续入组的134例初次单侧全膝关节置换术患者,比较术中单次1.5 g局部氨甲环酸、全身氨甲环酸与安慰剂的围手术期估计失血量。局部与全身氨甲环酸失血量相当,均显著低于安慰剂组,症状性深静脉血栓和肺栓塞发生率无显著差异。
要点
- 术中单次1.5 g局部或全身氨甲环酸均有效减少全膝关节置换术围手术期失血量。
- 局部氨甲环酸组失血量723 mL与全身氨甲环酸组749 mL相当。
- 两治疗组失血量均显著低于安慰剂组1090 mL。
核心结论
- 在择期全膝关节置换术背景下,术中单次1.5 g局部或全身给予氨甲环酸均有效减少失血量,且不增加并发症。
研究设计与样本
- 双盲、安慰剂对照、多中心随机对照试验,研究术中单次1.5 g氨甲环酸的局部与全身给药途径的疗效。
- 纳入初次单侧全膝关节置换术患者,2014年7月至2015年11月从5家新西兰中心连续入组,共134例。
- 三个前瞻性平行组:局部氨甲环酸组、全身氨甲环酸组和安慰剂组,主要结局为围手术期估计失血量,采用意向性治疗分析比较组间结局(P值<.05)。
主要发现
- 全身氨甲环酸组估计失血量为749 mL(95%CI 637-860),局部氨甲环酸组为723 mL(95%CI 620-826),两组相当。
- 与安慰剂组1090 mL(95%CI 923-1257)相比,全身氨甲环酸组失血量显著降低(P=.001),局部氨甲环酸组失血量显著降低(P=.0003)。
- 次要结局包括症状性深静脉血栓和肺栓塞发生率无显著差异(P=.759)。
关键数值与推荐
- 术中单次氨甲环酸剂量为1.5 g。
- 主要结局为围手术期估计失血量,采用意向性治疗分析,P值<.05为差异有统计学意义。
临床怎么用
- 原文结论为在择期全膝关节置换术中,术中单次1.5 g局部或全身氨甲环酸均有效减少失血量且不增加并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative anemia following elective arthroplasty can lead to prolonged hospital stay and delays in rehabilitation and is often poorly tolerated in patients with cardiovascular disease. Tranexamic acid (TXA) has been shown to reduce perioperative blood loss in total knee arthroplasty (TKA). However, questions over its optimal route of administration remain. METHODS: A double-blinded, placebo, multicentered, randomized, controlled trial investigating the efficacy of topical and systemic routes of a single intraoperative dose (1.5 g) of TXA was conducted. Patients undergoing primary, unilateral TKA were screened for eligibility. Eligible patients were consecutively enrolled from 5 New Zealand centers between July 2014 and November 2015. Three prospective groups running in parallel (topical TXA [tTXA], systemic TXA [sTXA], and placebo) were investigated for a primary outcome of estimated perioperative blood loss. An intention-to-treat analysis was used to compare outcomes between the study groups (P value <.05). RESULTS: One hundred and thirty-four patients across the 5 hospitals were recruited into the study. Estimated blood loss was equivalent in the 2 treatment groups, sTXA (749 mL [95% confidence interval, 637-860]) and tTXA (723 mL [620-826]). Compared to the placebo group (1090 mL [923-1257]), blood loss was significantly lower in both treatment groups (P = .001 and P = .0003, respectively). There were no significant differences in secondary outcomes, including rates of symptomatic deep vein thrombosis and pulmonary embolism (P = .759). CONCLUSION: In the setting of elective TKA, a single 1.5-g dose of tTXA given intraoperatively either systemically or topically effectively reduces blood loss without an increase in complications.
引用
- Stowers MDJ, Aoina J, Vane A, et al. Tranexamic Acid in Knee Surgery Study-A Multicentered, Randomized, Controlled Trial. J Arthroplasty. 2017. PMID: 28662956. doi:10.1016/j.arth.2017.05.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。